GlassScriptPhysician profile
Melissa Granados
NPI 1790327161
$1,668.86
in general payments reported to CMS, 2019-2025
14 companies · $616 in 2025
The $616 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $158 · 2024: $894 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $403.78 | 2024-2025 | Tecentriq, Itovebi |
| E.R. Squibb & Sons, L.L.C. | $254.93 | 2024 | Reblozyl |
| Mimedx Group, INC. | $251.45 | 2024-2025 | |
| Organogenesis INC. | $195.76 | 2023-2025 | Affinity, Apligraf, Nushield |
| Abbvie INC. | $141.89 | 2023-2024 | |
| Smith+Nephew, INC. | $126.10 | 2024-2025 | Collagenase Santyl, Renasys Touch, Renasys Go V2 Home |
| Sobi, INC | $114.97 | 2024 | |
| Convatec INC. | $59.62 | 2024 | |
| Biowound Solutions, INC. | $32.86 | 2025 | Bio-Connekt |
| Tg Therapeutics, INC. | $24.14 | 2025 | |
| Integra Lifesciences Corporation | $20.57 | 2025 | Tcc-Ez |
| Kerecis Limited | $16.53 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Paratek Pharmaceuticals, INC. | $14.54 | 2025 | Nuzyra |
| Ets Wound Care LLC | $11.72 | 2025 | Mirragen Advanced Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Granados listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.